title: Chronic epidural bupivacaine-opioid infusion in intractable cancer pain.
abstract: This study examined the efficacy and toxicity associated with chronic epidural opioid-bupivacaine infusions. In a series of 68 patients with cancer pain refractory to epidural opioids alone, analgesia was effectively regained by infusing a opioid-bupivacaine combination. Sixty-one patients (90%) were considered treatment successes, according to conventional criteria. Median length of therapy was 60-120 days, with the longest infusion lasting 277 days. Chronic bupivacaine infusion concentrations ranged from 0.1 to 0.5% with infusion rates varying from 4 to 18 ml/h. The majority of patients experienced pain relief with little or no sympathetic or sensorimotor impairment after the first 24 h at bupivacaine concentrations of 0.125-0.25% and were managed in home or chronic care settings without the need for re-hospitalization. In patients receiving higher bupivacaine concentrations, sympathetic, sensory and motor blockade were well tolerated during chronic infusion. Sensory loss was consistently observed only at bupivacaine concentrations exceeding 0.25%, and motor impairment occurred only at concentrations exceeding 0.35%. Postural hypotension was observed in 6 patients (9%) for the first 24 h only, which supports the requirement for monitoring and fluid therapy during initiation of the bupivacaine infusion. No patient experienced CNS or systemic toxicity, despite plasma total bupivacaine concentrations as high as 10.8 micrograms/ml. Serial plasma bupivacaine levels were measured in 15 patients during chronic infusion. There was considerable inter- and intra-individual variability in plasma bupivacaine concentrations and bupivacaine clearance. We conclude that epidural opioid-bupivacaine infusion is an effective and safe technique for long-term administration of analgesics in the refractory cancer patient.
authors.affiliation: Pain Consultation Service, Swedish Hospital Medical Center, Seattle, WA 98104, USA Department of Anesthesiology, Swedish Hospital Medical Center, Seattle, WA 98104, USA Department of Anesthesiology, University of Washington, Seattle, WA 98195 USA Department of Anesthesiology and Medicinal Chemistry, University of Washington, Seattle, WA 98195 USA.
authors.forename: Stuart L
authors.initials: SL
authors.lastname: Du Pen
authors.forename: Evan D
authors.initials: ED
authors.lastname: Kharasch
authors.forename: Anna
authors.initials: A
authors.lastname: Williams
authors.forename: Donald G
authors.initials: DG
authors.lastname: Peterson
authors.forename: Dean C
authors.initials: DC
authors.lastname: Sloan
authors.forename: Hans
authors.initials: H
authors.lastname: Hasche-Klunder
authors.forename: Alexander W
authors.initials: AW
authors.lastname: Krembs
mesh_terms: D015360:Analgesia, Epidural; D001794:Blood Pressure / Q000187:drug effects; D002045:Bupivacaine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D009294:Narcotics / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000503:physiopathology*; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology
chemical_list: D009294:Narcotics; D002045:Bupivacaine